论文部分内容阅读
美国《药物评价》自1970年首版发行迄今虽已十八年了,但其原来的宗旨仍旧没有什么改变—提供医师们及其他卫生保健工作者以当代最新的资料,提供药物临床应用的公正资料。该书作为资料来源以供给有比较的评价性参考资料,为药物治疗服务。《药物评价》的评论过程:由美国医学会药学部的专业工作者根据当前的科技文献将有关章节写成后,再由有关顾问和适当的药物制造商的医务工作者加以审阅。经修订一致后,由被选派者或美国临床药理治疗学会的会员将有关章节再予以审定。有著名的512位顾问对该版有关章节的草稿做了评审。因而,这一出版物是美国医学会、一个庞大的顾问团和美国临床药理治疗学会等三个机构联合编篡的
Although it has been eighteen years since its first edition was first published in 1970, the US Drug Evaluation remains unchanged in its original purpose of providing physicians and other health care workers with the most up-to-date information about the justice of the clinical use of medicines data. The book as a source of information to provide a comparative evaluation of reference materials for medical treatment services. The review process of “drug evaluation”: After the relevant section of the current medical literature is written by the professional staff of the Department of Pharmacy of the American Medical Association and reviewed by the medical staff concerned with the consultant and the appropriate drug manufacturer. After revising, the relevant section will be validated again by the selected person or the member of American Society of Clinical Pharmacology. A well-known 512 consultants reviewed the draft chapters of the edition. Thus, this publication is co-edited by three bodies, the American Medical Association, a large advisory group and the American Society of Clinical Pharmacology and Therapeutics